Cambridge Heart, Inc. is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.The company's mission is to reduce the incidence of sudden cardiac arrest (SCA) by developing accurate, non‐invasive technologies to identify individuals at risk of life‐threatening arrhythmias.


Our diagnostic products incorporate proprietary technology for the measurement of Microvolt T-Wave Alternans™ (MTWA), a subtle beat-to-beat fluctuation in the T-wave segment of the electrocardiogram (ECG), which is a marker of SCA risk.